Legend Biotech

Join us at #ASCO26 for our Investor Relations event, where we will discuss how CAR-T therapy is helping to transform the multiple myeloma treatment landscape. 📅 Sunday, May 31, 2026 🕑 6:15 p.m. CT / 7:15 p.m. ET Learn more and register for the webcast here: https://bit.ly/4wyn5xk American Society of Clinical Oncology (ASCO) #ASCO26 #CellTherapy #Biotech #MultipleMyeloma

#LegendNews: New investigational and clinical data across our CAR-T portfolio will be presented at #ASCO26, including early findings for investigational CAR-T therapy LB2102 in solid tumors. In addition, new data from our CAR-T cell therapy further reinforces its established efficacy and safety profile in multiple myeloma. As we continue scaling commercially, we remain focused on improving long-term outcomes, expanding access for patients, and investing in the future of cell therapy innovation. Come find us at ASCO Booth #21955 to learn more and read more at: https://bit.ly/4f16QCG American Society of Clinical Oncology (ASCO) #CellTherapy #CancerResearch

Most people don’t see the moments that come with a multiple myeloma diagnosis. They may not see the progress either – the research, collaboration, and advancements that are expanding treatment options.  This progress is evident in the treatment of over 10,000 patients with our CAR-T cell therapy, showcasing the power of scientific innovation. Increasing awareness of this complex disease can support earlier recognition, foster more informed discussions, and sustain the momentum in cell therapy. Learn more: https://legendbiotech.com/ #MultipleMyeloma #CellTherapy #CART #BloodCancer #LegendBiotech

At #ASCO26, we'll present new data across our cell therapy portfolio, including investigational LB2102 findings in solid tumors and our CAR-T program in multiple myeloma. As we continue scaling commercially, we remain focused on advancing cell therapy innovation, expanding access for patients, and investing in the future of oncology research. Looking forward to sharing more at the American Society of Clinical Oncology (ASCO). #CellTherapy #Oncology

At this year’s Nerdland Festival, we’re bringing CAR‑T therapy to life—from vein to vein—and discovering what it can mean for patients and their families. Through interactive experiences, visitors gain a hands‑on understanding of how advanced science translates into real‑world treatments, making complex concepts accessible to everyone. Behind every breakthrough are our dedicated manufacturing teams in the U.S. and the EU, who work tirelessly every day to make a meaningful difference for patients and their families. 📍 Area 42 | May 23–25 🔗 Learn more: https://lnkd.in/e6DAc8VT #LegendBiotech #NerdlandFestival #CARTtherapy

We’re heading into American Society of Clinical Oncology (ASCO) with a lot to share. From the continued progress in multiple myeloma to early momentum in solid tumors, our focus stays the same: advancing what’s possible in cell therapy. More to come at ASCO! #ASCO26 #CellTherapy #Oncology

We made it to Times Square—but this moment represents something bigger. Multiple myeloma doesn’t define the people living with it. That’s why we’re bringing greater visibility to the disease—and to the progress being made for patients—on one of the world’s biggest stages. At Legend Biotech, that commitment extends beyond a single disease, as we continue to advance cell therapy and invest in a broader pipeline focused on meaningful patient impact. #MultipleMyeloma #LegendBiotech

Advancing patient care is a team effort. This week at the Oncology Nursing Society Congress in San Antonio, the Legend team is connecting with oncology nurses and care teams to share perspectives, learn from each other, and support the delivery of advanced therapies. Stop by and visit our booth #1103 to learn more. #ONS2026 #PatientsFirst

#LegendNews: Today, we reported our Q1 2026 financial results. The quarter reflects continued progress across our business, including advancing our pipeline, strengthening our operational capabilities, and supporting the global delivery of cell therapies. As we move through 2026, we remain focused on building this momentum and continuing to bring innovative therapies to patients worldwide. Read the full report: https://lnkd.in/emdtyJjX #FinancialResults #BiotechLeadership #Earnings $LEGN 

All eyes on Times Square. Our mission spans today’s impact and tomorrow’s innovation.    From advancing cell therapy in multiple myeloma to expanding our broader pipeline, Legend Biotech is focused on delivering transformative treatments for patients.    #MultipleMyeloma #LegendBiotech